









Markets
/
Stocks
/
nasdaq-flgc
/

Flora Growth Corp

FLGC

25.770USD

-4.040-13.55%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

581.60MMarket Cap

LossP/E TTM



Flora Growth Corp

25.770

-4.040-13.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

52 / 72

Overall Ranking

266 / 4721

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

93.000

Target Price

+211.98%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Flora Growth Corp. is a cannabis company that manufactures and distributes consumer packaged goods and distributes medicinal cannabis and pharmaceutical product. Its brand consists of JustCBD, Vessel, No Cap Hemp Co., and Australian Vaporizers. JustCBD is a consumer-packaged goods brand with over 300 products, including cannabidiol gummies, topicals, tinctures, and vape products. JustCBD products are available for purchase in smoke and vape shops, clinics, spas, and pet stores, as well as other independent non-traditional retail channels. Vessel is the cannabis accessory and technology brand servicing the United States and Canada through direct-to-consumer and retail sales. Vessel's products include cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herb categories, which are sold to consumers, dispensaries, smoke shops, and cannabis brands. Australian Vaporizers is an online retailer of vaporizers, hardware, and accessories in Australia.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 78.15% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 59.51M.

Undervalued

The company’s latest PE is -29.07, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 97.39K shares, decreasing 39.78% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.28K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 6.59, which is lower than the Healthcare Providers & Services industry's average of 7.42. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 14.80M, representing a year-over-year decrease of 5.66%, while its net profit experienced a year-over-year decrease of 8.29%.

Score

Industry at a Glance

Previous score

6.59

Change



Financials

4.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.74

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.53

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Providers & Services industry's average of 2.35. Its current P/E ratio is -33.62, which is -98.12% below the recent high of -0.63 and 97.80% above the recent low of -0.74.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 52/72

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Providers & Services industry's average of 7.58. The average price target for Flora Growth Corp is 93.00, with a high of 156.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

93.000

Target Price

+211.98%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Flora Growth Corp

FLGC

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Natera Inc

NTRA

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 9.42, which is higher than the Healthcare Providers & Services industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 35.13 and the support level at 22.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.42

Change

-1.9

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.014

Neutral

RSI(14)

60.913

Neutral

STOCH(KDJ)(9,3,3)

59.840

Sell

ATR(14)

2.218

High Vlolatility

CCI(14)

79.627

Neutral

Williams %R

56.376

Sell

TRIX(12,20)

1.999

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

26.626

Sell

MA10

24.732

Buy

MA20

23.086

Buy

MA50

14.749

Buy

MA100

7.702

Buy

MA200

4.292

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Providers & Services industry's average of 8.03. The latest institutional shareholding proportion is 16.83%, representing a quarter-over-quarter decrease of 31.77%. The largest institutional shareholder is The Vanguard, holding a total of 2.28K shares, representing 0.39% of shares outstanding, with 23.47% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Starke (Clifford A)

2.25M

+66.82%

Empery Asset Management, L.P.

349.06K

-62.32%

Dorf (Sammy)

250.00K

Vaiman (Dany)

170.85K

Geode Capital Management, L.L.C.

165.56K

+26.44%

Woo (Edward)

136.72K

The Vanguard Group, Inc.

Star Investors

88.78K

Renaissance Technologies LLC

Star Investors

82.01K

-28.69%

AdvisorShares Investments, LLC

70.42K

XTX Markets LLC

23.52K

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.04, which is lower than the Healthcare Providers & Services industry's average of 4.17. The company's beta value is 2.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.